340
Participants
Start Date
August 2, 2017
Primary Completion Date
August 8, 2022
Study Completion Date
August 8, 2022
Tocilizumab
Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
MTX
Participants will receive MTX stable doses at 10 to 25 mg orally.
Placebo Matched to MTX
Placebo matched to MTX.
Placebo Matched to Tocilizumab
Placebo matched to tocilizumab.
China-Japan Friendship Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing Union Hospital, Beijing
Shengjing Hospital of China Medical University, Shenyang
the First Hospital of Jilin University, Changchun
The 1st Affiliated Hospital of Harbin Medical University, Harbin
Jiangsu Province Hospital, Nanjing
The First Affiliated Hospital of Anhui Medical University, Hefei
Affiliated Hospital of Bengbu Medical College, Bengbu
Qilu Hospital of Shandong University, Jinan
Tianjin Medical University General Hospital, Tianjin
The First Hospital of Jiaxing, Jiaxing
Pingxiang People Hospital, Pingxiang
Guangdong General Hospital, Guangzhou
West China Hospital, Sichuan University, Chengdu
The First Affilliated Hospital of Kunming Medical College, Kunming
The First Affiliated Hospital of Baotou Medical College, Baotou
Affiliated Hospital of Inner Mongolia Medical College, Hohhot
The Second Hospital of Shanxi Medical University, Taiyuan
Hoffmann-La Roche
INDUSTRY